Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10782 | 0.87 | PIK3CD (0.38) | PIK3CDSLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL21938409 | 0.80 | SHBG (0.35) | PIK3CDSLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL19702055 | 0.79 | PIK3CD (0.47) | PIK3CD | |
| SCHEMBL10064766 | 0.79 | PIK3CD (0.66) | PIK3CDPOLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6119943 | 0.79 | PIK3CD (0.51) | PIK3CDPOLBSLC6A2SLC6A4L3MBTL1 | |
| SCHEMBL6976305 | 0.79 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL7992646 | 0.78 | PIK3CD (0.50) | PIK3CDPOLBSLC6A2SLC6A4L3MBTL1 | |
| SCHEMBL26854516 | 0.78 | PIK3CD (0.50) | PIK3CDSLC6A2SLC6A4SLC6A3L3MBTL1 | |
| SCHEMBL19658845 | 0.76 | TP53 (0.39) | POLBCYP2D6SMN1; SMN2 | |
| SCHEMBL1911533 | 0.76 | PIK3CD (0.47) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | PIK3CD 2458/4885POLB 1417/4885SLC6A2 1971/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | PIK3CD 2458/4885POLB 1417/4885SLC6A2 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.